Since the use of selective PPARα agonists has proven quite ineffective against NAFLD [197] the use of mixed receptor agonists (PPARα and PPARβ/γ) is underway in the therapy for NASH patients and recent results have been reported [206]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.